Yale University / Connecticut Mental Health Center
Welcome,         Profile    Billing    Logout  
 1 Trial 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Maboudi, Heidi
NCT04641143: Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Recruiting
3
700
US
Troriluzole, Placebo
Biohaven Pharmaceuticals, Inc.
Obsessive-Compulsive Disorder
06/25
06/25
Pedraza, Luis
NCT04641143: Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Recruiting
3
700
US
Troriluzole, Placebo
Biohaven Pharmaceuticals, Inc.
Obsessive-Compulsive Disorder
06/25
06/25
RETHINK-1, NCT04994483: Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease

Completed
3
804
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
10/24
10/24
NCT05443724 / 2022-001151-16: A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

Recruiting
2
850
Europe, US, RoW
CVL-231 30 mg, Emraclidine
Cerevel Therapeutics, LLC
Schizophrenia
02/26
02/26
LiBBY, NCT05644262: Life's End Benefits of cannaBidiol and tetrahYdrocannabinol

Recruiting
2
150
US
T2:C100, TRC/CBD oral combination, Placebo
University of Southern California, Medical University of South Carolina, Alzheimer's Clinical Trials Consortium, Alzheimer's Therapeutic Research Institute, National Institute on Aging (NIA)
Agitation, Dementia
12/25
12/25
Kichuk, Stephen
NCT04641143: Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Recruiting
3
700
US
Troriluzole, Placebo
Biohaven Pharmaceuticals, Inc.
Obsessive-Compulsive Disorder
06/25
06/25
NCT04131829: Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD

Recruiting
1/2
100
US
Fluoxetine - immediate treatment, fluoxetine, prozac, Fluoxetine - delayed treatment
Yale University, National Institute of Mental Health (NIMH)
Obsessive-Compulsive Disorder
06/25
12/25
Reyno, Yelenia
NCT04641143: Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Recruiting
3
700
US
Troriluzole, Placebo
Biohaven Pharmaceuticals, Inc.
Obsessive-Compulsive Disorder
06/25
06/25
NCT05399368: An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

Terminated
2
229
Canada, US
RPT193, Placebo
RAPT Therapeutics, Inc.
Atopic Dermatitis
05/24
05/24

Download Options